Related Experiment Videos
The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy
M Yamazaki1, O Fukutomi, N Kondo
1Department of Pediatrics, Gifu University School of Medicine, Japan.
Insights
This study shows Bayesian analysis effectively predicts serum theophylline levels when switching from intravenous aminophylline to oral sustained-release theophylline, optimizing pediatric asthma treatment.
Area of Science:
- Pharmacology
- Pediatric Pulmonology
- Clinical Pharmacy
Background:
- Asthma management in children often involves intravenous aminophylline followed by oral theophylline.
- Accurate dosing is crucial for efficacy and safety, especially during medication conversion.
- Predicting optimal oral theophylline dosages from intravenous aminophylline data presents a clinical challenge.
Purpose of the Study:
- To evaluate the effectiveness of Bayesian analysis in predicting serum theophylline concentrations.
- To determine optimal oral sustained-release theophylline dosing regimens after intravenous aminophylline therapy.
- To assess the accuracy of predicted theophylline levels against measured values in pediatric asthma patients.
Main Methods:
- Twelve children with bronchial asthma received constant intravenous aminophylline.
- Oral sustained-release theophylline was initiated 3 hours after conversion.
- Pharmacokinetic parameters were estimated using Bayesian analysis of serum theophylline levels during intravenous therapy.
Main Results:
- Bayesian analysis accurately predicted serum theophylline concentrations during oral therapy.
- Predicted concentrations closely matched actual measured values.
- This method aids in determining effective oral theophylline dosages.
Conclusions:
- Bayesian analysis is a reliable tool for predicting theophylline pharmacokinetics during conversion from IV to oral therapy.
- This approach facilitates personalized oral theophylline dosing for pediatric asthma patients.
- Optimized dosing enhances therapeutic effectiveness and patient outcomes.
Abstract:
We studied the design of oral sustained-release theophylline dosing after conversion from constant aminophylline infusion. Twelve children with bronchial asthma (9 boys and 3 girls) were evaluated in this study. Each patient received a constant intravenous administration of aminophylline for 4-10 days. Three hours after conversion from constant aminophylline infusion, they received oral sustained-release theophylline twice daily at 12-hour intervals. Blood samples were obtained at least once during the aminophylline infusion, just before conversion from the aminophylline infusion, and 0, 3 and 6 hours, and 4-5 days after administering oral theophylline. Pharmacokinetic parameters were estimated using the serum theophylline concentrations that were obtained during constant aminophylline infusion. These estimates of pharmacokinetic parameters were used to predict the serum theophylline concentrations during oral theophylline therapy. Predicted serum theophylline concentrations using individual pharmacokinetic parameters were fitted with actual measured values in this study. When switching a patient from intravenous aminophylline to sustained-release oral theophylline, the use of Bayesian analysis of serum theophylline concentration values obtained during intravenous therapy works well in predicting serum theophylline concentrations and in determining oral dosages that maximize the drug's effectiveness.